Clinical Evaluation of TrueVision System: LRI and Capsulorhexis Templates
Launched by TRUEVISION SYSTEMS, INC · May 12, 2010
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy eye with no previous ocular surgery
- • Natural lens for which phacoemulsification extraction and posterior IOL implantation is planned
- • Clear intraocular media other than cataract
- • Potential visual acuity 20/30 or better
- • Able to comply with preop and postop examination procedures
- • Signed and dated informed consent
- Exclusion Criteria:
- • Keratometric astigmatism \> 2.5 diopters
- • Corneal pathology potentially affecting topography including corneal degeneration
- • Irregular astigmatism
- • Macular degeneration or any other macular disease which reduces potential acuity
- • Previous corneal surgery (including LASIK, radial keratotomy, penetrating keratoplasty, etc)
- • Use of systemic or ocular medications that affects vision
- • Acute or chronic systemic or ocular disease or illness that would increase risk or confound study results
- • Use of Flomax or any other medication which negatively impacts surgical outcomes
- • History of ocular trauma or ocular surgery
About Truevision Systems, Inc
TrueVision Systems, Inc. is a pioneering medical technology company dedicated to advancing the field of ophthalmology through innovative imaging solutions and surgical systems. With a commitment to enhancing the precision and effectiveness of eye care, TrueVision develops cutting-edge technologies that support ophthalmic professionals in delivering superior patient outcomes. The company's focus on research and development drives its engagement in clinical trials, aimed at validating and optimizing its products for a range of surgical applications. TrueVision is dedicated to improving vision health and quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Eugene, Oregon, United States
Patients applied
Trial Officials
Mark Packer, MD
Study Director
Oregon Eye Associates
Robert Weinstock, MD
Principal Investigator
Eye Institute of West Florida
Jason Stahl, MD
Principal Investigator
Durrie Vision
Douglas Katsev, MD
Principal Investigator
Sansum Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials